Talzenna scores in first-line prostate cancer irrespective of HRR status, but for now we only have Pfizer’s word for it.
A November adcom could decide whether Zejula will lose yet more ground to Lynparza.
Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
Setbacks hit two of the Swiss biotech’s clinical-stage darpin projects in a single day.
Rubraca has scored in an all-comers, first-line ovarian cancer maintenance setting, but Clovis has bigger problems.
Lynparza squares off against Zejula while Rubraca and Talzenna wait in the wings, but should first-line use be restricted by biomarkers?